Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

N/ACompletedNCT01934478

Qingdao Central Hospital5 enrolled

Overview

Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histological confirmed advanced breast cancer * cancer sample can be obtained by fine needle biopsy * IHC and FISH confirmed Her2 negative * radiotherapy indication for local residual cancer Exclusion Criteria: * no radiotherapy indication * patient refuse

Locations (1)

Qingdao Central Hospital, Qingdao Cancer Hospital

Qingdao, Shandong, China

Outcomes

Primary Outcomes

Her2 changes during radiotherapy

biopsy is obtained by fine needle biopsy，Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).

Time frame: every week up to 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.